Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03443518
Other study ID # 180101
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 6, 2018
Est. completion date December 10, 2018

Study information

Verified date February 2019
Source Dr. Erfan and Bagedo General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Endovascular aneurysm repair (EVAR) was introduced in 1990 for the first time as a minimally invasive procedure instead of the conventional open surgical repair, with the aim to decrease morbidity and mortality . Nowadays EVAR has become an acceptable management for patients with infra-renal aortic aneurysms (AAA) . A lot of anesthetic techniques have been used successfully for EVAR. EVAR requires sedative analgesic medications to achieve an acceptable level of comfort to the patient and cardiorespiratory stability.

This is prospective randomized single blinded study of patients presenting with aorto-iliac aneurysm who will undergo EVAR. Patient's demographic data will be assessed, as well as clinical presentation, intraoperative complications.

30 patients undergoing elective EVAR will be included and will be divided equally into 2 groups.

First group is the psoas compartment block (PCB) (15 patients): 30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark.

Second group is the LA and remifentanil group (LR) (15 patients): lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration then remifentanil infusion with rate 0.03-0.1 μg kg−1 min−1. to achieve visual analog scale (VAS) 3 or less.

Vital date will be recorded as baseline then every 5 minutes till the end of the procedure. VAS will be recorded as baseline then every 5 minutes till the end of the procedure. Also stress response which will be measured subjectively as vital data and VAS and objectively as cortisol level in the blood which will be measured as base line and immediate after the end of the procedure.


Description:

Anatomical, imaging and clinical studies suggest that psoas compartment block (PCB) which was done at L2-L3 level has a high possibility to include L1-L2 roots, and thus can be suitable for inguinal surgery. In our study, the investigators introduce a modified PCB which will be performed in lateral decubitus by a 120 mm stimulated needle inserted at the junction between the lateral third and the medial two-thirds of a line drawn at L2-L3 interspace, between the interspinous line and a line passing through the posterior superior iliac spine (PSIS), parallel to the interspinous line . If twitching of the anterior thigh area is observed, the needle is moved slight cranially. When twitching of the inguinal field is observed, bupivacaine 0.5% 30 ml, will be injected


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 10, 2018
Est. primary completion date November 10, 2018
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- All elective patients presenting with aortoiliac aneurysm who will undergo percutaneous EVAR.

Exclusion Criteria:

- Exclusion criteria included the presence of an aneurysm of the common femoral artery or severe atherosclerotic disease with total occlusion, emergency EVAR, uncooperative patient, patient on anticoagulation therapy, cerebrovascular disease, poorly controlled hypertension (systolic arterial pressure =160 mmHg), poorly controlled diabetes mellitus (random blood glucose =200 mg/dL) and renal insufficiency (creatinine >1.5 mg/dL).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Psoas Compartment Block (PCB)
30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark for Psoas Compartment Block (PCB)
Local Anesthesia infiltration
Lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration.
Drug:
Normal saline 0.9% IV infusion
Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 µg/ kg/min).
Remifentanil infusion
Remifentanil infusion with rate 0.03-0.1 µg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less

Locations

Country Name City State
Saudi Arabia DR Erfan hospital Jeddah
Saudi Arabia Erfan hospital Jeddah

Sponsors (1)

Lead Sponsor Collaborator
Dr. Erfan and Bagedo General Hospital

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Visual Analogue Scale (VAS) The primary outcome was Visual Analog Scale (VAS) to assess perioperative analgesia and pain management.
Pain was assessed using the 100-mm visual analog scale, ranging from 0 to 100. The lowest score is 0 (no pain/excellent analgesia) and the highest score is 100 (Max pain).
Assessment to be done at baseline (immediate before starting the procedure), then every 10 min through study till 4 hours after given the anesthesia.The event was determent via asking patient about pain experience every time using 100 mm VAS
Secondary Arterial blood pressure Arterial blood pressure monitoring in mmHg will be recorded at baseline (immediate before starting the procedure), then every 5 min through study till 4 hours after given the anesthesia.
Secondary Satisfactions Score Patient and surgeon satisfactions were assessed using the satisfaction score by asking them according to their degree of satisfaction based on this scale, which ranges from 0 to 100 (0 being the lowest score and 100 being the highest score). Time frame include 2 time points, first time point: immediate at the end of the procedure and the second time point: 2 hours after the end of the procedure
Secondary heart rate (HR) heart rate monitoring in beat / min Will be recorded at baseline (immediate before starting the procedure), then every 5 min through study till 4 hours after given the anesthesia.
Secondary Oxygen saturation Oxygen saturation monitoring in % Will be recorded at baseline (immediate before starting the procedure), then every 5 min through study till 4 hours after given the anesthesia.
See also
  Status Clinical Trial Phase
Recruiting NCT03453541 - Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy Phase 4
Completed NCT05880433 - The Effects of Mydriatic Eye Drops in Retinopathy of Prematurity Examinations
Recruiting NCT04369222 - The Copenhagen Analgesic Study
Completed NCT03493490 - Neodolpasse® Infusion Solution Versus Diclofenac 75 mg Infusion in the Treatment of Postoperative Pain After Elective Knee Surgery Phase 4
Recruiting NCT05924412 - Parecoxib in Total Knee Arthroplasty Phase 4
Completed NCT03203967 - Epidural Morphine for Postoperative Analgesia After Total Knee Arthroplasty N/A
Completed NCT03841812 - Comparation Analgesia Efficiency With Propofol Combine Sevoflurane vs Propofol Phase 3
Completed NCT02717637 - Oxycodone in Serum After Postoperative Oral Oxycodone in Caesarean Sections Under Spinal Anesthesia N/A
Completed NCT03665792 - The Correlation Between Sevoflurane and qNOX
Completed NCT04226443 - The Use of Midazolam and Remifentanil During Dialysis Access Procedures N/A
Recruiting NCT05575700 - Safety of Ibuprofen After Major Orthopaedic Surgeries Phase 4